武田薬品工業
Takeda Pharmaceutical Co Ltd ADRUSUSDTakeda Pharmaceutical Co Ltd ADR (US:TKPHF) — Biotechnology: Pharmaceutical Preparations. Antal børser, hvor selskabets aktier handles: 3. På denne side — kurs og diagram, udbytte, største aktionærer og historik over antal aktier.
Om Virksomheden
- Websted
- takeda.co.jp
- Sektor
- Health Care · Biotechnology: Pharmaceutical Preparations
- Hovedkontor
- TOKYO, Japan
- Administrerende Direktør
- Julie Kim
- Ansatte
- 47 029
- Grundlagt
- 1781
- Udestående Aktier
- Free Float
- 3.16 mia.
- Markedsværdi
- 9.52 bio. JPY
- Insidere
- 0.07%
- Institutionelle Investorer
- 3.31%
- Branche (SIC)
- Pharmaceutical Preparations
- Juridisk Form
- T417
- ISIN
- US8740602052
- LEI
- 549300ZLMVP4X0OGR454
- Udbetalingsgrad
- underskud
- FCF
- 627 mia. JPY
- Payout / FCF
- 49%
- Gæld
- 4.94 bio. JPY7.1 år FCF
- Udbyttestreak
- —
- Indtjening, FCF og udbetalt udbytte — for de 12 måneder frem til 30.06.2026 (selskabets seneste rapport).
Beskrivelse
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.
Udbytte
Takeda Pharmaceutical Co Ltd ADR (TKPHF) udbetaler udbytte to gange om året. Pr. År (12 måneder op til og med den senest annoncerede betaling): 202 JPY pr. Aktie (betalinger: 2). Baseret på betalingshistorikken forventes næste ex-udbyttedato omkring 31.03.2027.
| Ex-Dato | Udbetaling | Beløb | % | Type | Ticker |
|---|---|---|---|---|---|
| 2026-09-30 | — | 102.0000 JPY | 1.7/3.5 % | halvårlig | US:TKPHF |
| 2026-03-31 | 2026-06-25 | 100.0000 JPY | 1.8/3.7 % | halvårlig | US:TKPHF |
| 2025-09-30 | 2025-12-01 | 100.0000 JPY | 2.2/4.3 % | halvårlig | US:TKPHF |
| 2025-03-31 | 2025-06-26 | 98.0000 JPY | 2.0/3.9 % | halvårlig | US:TKPHF |
| 2024-09-30 | 2024-12-02 | 98.0000 JPY | 2.4/≈4.7 % | halvårlig | US:TKPHF |
Største Ejere
| Ejer | Andel | Aktier | Rapportdato |
|---|---|---|---|
| Capital Research Global… | 0.6% | 19.3 mio. | 2026-06-30 |
| AMERICAN MUTUAL FUND | 0.57% | 18.16 mio. | 2026-06-30 |
| FMR, LLC | 0.3% | 9.6 mio. | 2026-06-30 |
| Morgan Stanley | 0.22% | 6.99 mio. | 2026-06-30 |
| Adage Capital Partners G… | 0.19% | 6.05 mio. | 2026-06-30 |
| Goldman Sachs Group Inc | 0.16% | 5.13 mio. | 2026-06-30 |
| Brandes Investment Partn… | 0.14% | 4.54 mio. | 2026-06-30 |
| Arrowstreet Capital, Lim… | 0.12% | 3.73 mio. | 2026-06-30 |
| Blackrock Inc. | 0.12% | 3.69 mio. | 2026-06-30 |
| Renaissance Technologies… | 0.08% | 2.57 mio. | 2026-06-30 |
| Qube Research & Technolo… | 0.07% | 2.21 mio. | 2026-06-30 |
| First TRT Exch-Trd Fd.-F… | 0.06% | 1.88 mio. | 2026-08-31 |
| VanEck ETF Trust-VanEck… | 0.06% | 1.79 mio. | 2026-08-31 |
| Steward Funds Inc-Stewar… | 0.02% | 711 871 | 2026-04-30 |
| Mercer Funds-Mercer Non-… | 0.02% | 586 098 | 2026-06-30 |
| American Century ETF Tru… | 0.02% | 553 008 | 2026-08-31 |
| GOLDMAN SACHS TRUST-Gold… | 0.02% | 494 442 | 2026-07-31 |
| WEBER CHRISTOPHE PIERRE… | ≈0.01% | 418 803 | 2026-04-27 |
| KIM JULIE SO-YOUNG (Chie… | ≈0.01% | 391 489 | 2026-08-10 |
| Trust for Professional M… | 0.01% | 170 113 | 2026-05-31 |
| MUTUAL FUND SERIES TRUST… | 0.01% | 169 000 | 2026-06-30 |
| PLATFORD GILES RICHARD (… | ≈0.01% | 315 838 | 2026-08-10 |
| BITETTI TERESA MARIE (Of… | ≈0.01% | 252 010 | 2026-08-10 |
| FURNEY NATALIE ANNE MARI… | ≈0.01% | 204 298 | 2026-08-10 |
| DUPREY LAUREN RUSCKOWSKI… | ≈0.01% | 191 522 | 2026-09-14 |
| PACHECO RHONDA JANICE (O… | ≈0.01% | 182 507 | 2026-08-10 |
| PIGNAGNOLI AGOSTI MARCEL… | ≈0.01% | 176 977 | 2026-08-10 |
| RICCI GABRIELE (Chief Te… | ≈0.01% | 171 654 | 2026-08-10 |
| Carillon Series Trust-Ca… | 0% | 160 000 | 2026-06-30 |
| PLUMP ANDREW STEWART (Of… | — | — | 2026-09-02 |
